Titre :

CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases.

Auteur(s) :

Chevalier, Kevin [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Genin, Michaël [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Petit Jean, Thomas [Auteur]
Direction des Systèmes d’Information, Pôle Innovation et Données [AP-HP]
Avouac, Jérôme [Auteur]
Hôpital Cochin [AP-HP]
Flipo, René-Marc [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Georgin-Lavialle, Sophie [Auteur]
CHU Tenon [AP-HP]
El Mahou, Soumaya [Auteur]
Centre Hospitalier Tourcoing
Pertuiset, Edouard [Auteur]
Centre Hospitalier René Dubos [Pontoise]
Pham, Thao [Auteur]
Hôpital Sainte-Marguerite [CHU - APHM] [Hôpitaux Sud ]
Servettaz, Amélie [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Marotte, Hubert [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
Domont, Fanny [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Chazerain, Pascal [Auteur]
Groupe Hospitalier Diaconesses Croix Saint-Simon
Devaux, Mathilde [Auteur]
Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy]
Mekinian, Arsene [Auteur]
CHU Saint-Antoine [AP-HP]
Sellam, Jérémie [Auteur]
CHU Saint-Antoine [AP-HP]
Fautrel, Bruno [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Rouzaud, Diane [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Ebstein, Esther [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Costedoat-Chalumeau, Nathalie [Auteur]
Hôpital Cochin [AP-HP]
Richez, Christophe [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Mariette, Xavier [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Seror, Raphaèle [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]

Titre de la revue :

Frontiers in Medicine

Nom court de la revue :

Front Med (Lausanne)

Numéro :

10

Pagination :

1152587

Date de publication :

2023-04-11

ISSN :

2296-858X

Mot(s)-clé(s) en anglais :

rheumatic and musculoskeletal diseases
vasculitis
lupus
rituximab
inflammatory rheumatic diseases
auto-immune diseases
COVID-19

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Introduction Autoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed ...
Lire la suite >Introduction Autoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death. Materials and methods Two databases were analyzed: the EDS (Entrepôt des Données de Santé, Clinical Data Warehouse), including all patients followed in Paris university hospitals and the French multi-center COVID-19 cohort [French rheumatic and musculoskeletal diseases (RMD)]. First, in a combined analysis we compared patients with severe and non-severe COVID-19 to identify factors associated with severity. Then, we performed a propensity matched score case–control study within the EDS database to compare AIRD cases and non-AIRD controls. Results Among 1,213 patients, 195 (16.1%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe COVID-19 [aOR = 1.43 (1.08–1.87), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe COVID-19 [aOR = 1.11 (0.68–1.81)]. Conclusion In this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, auto-inflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2023-11-15T02:11:26Z
2024-04-05T11:27:35Z